New treatment for the chronically depressed

September 1, 2009
An Adelaide Clinic staffer demonstrates the transcranial magnetic stimulation treatment for depression.

(PhysOrg.com) -- A University of Adelaide study has found that mild and repeated doses of magnetic brain stimulation can be an effective treatment for chronic depression.

Psychiatry Professor Cherrie Galletly says 38 patients with a have shown a clear improvement after undertaking treatment with magnetic brain stimulation for 30 minutes at a time.

"At the start of the study, all participants met the criteria for moderate to and most had contemplated suicide," Professor Galletly says. "After treatment, 12 patients had made a full recovery and many others showed significant improvement. A six-month follow up of 11 patients showed the improvement was sustained."

The ongoing study, conducted at the Adelaide Clinic, involves people who have severe, long-term depression lasting up to 20 years. In 87% of cases, the participants had trialled five or more .

"Preliminary results indicate that 12 transcranial magnetic stimulation (TMS) treatments, given three days a week over a month, may be sufficient to achieve good results," Professor Galletly says.

The procedure involves placing an electromagnetic coil near the of a patient's scalp for half an hour. The magnetic energy stimulates the region of the brain which is involved in mood regulation and depression.

"The advantages of TMS are that, unlike electro convulsive treatment, no anaesthetic is required and there is no associated cognitive impairment," Professor Galletly says. "The only side effects that patients have experienced are slight headaches due to the effect of the pulsing magnet on their scalp. This can be alleviated with a simple headache tablet."

Professor Galletly says there are no medications involved with the procedure. However, most patients are taking antidepressants and can remain on these during TMS treatment. Only people referred by a psychiatrist are accepted for treatment and TMS is restricted to people with private health cover as it is not reimbursed by Medicare at this stage.

Although TMS has been available in the United States and Europe for some time, the procedure has only been available in South Australia in the past 12 months.

"There has been a lot of interest from psychiatrists in Australia because it has been a long time since we have seen new treatments for depression. This is a very exciting development for the profession," Professor Galletly says.

Provided by University of Adelaide (news : web)

Related Stories

Recommended for you

Abusive avatars help schizophrenics fight 'voices': study

November 24, 2017
"You're rubbish. You're rubbish. You're a waste of space." The computer avatar pulls no punches as it lays into the young woman, a schizophrenia sufferer, facing the screen.

Ten-month-old infants determine the value of a goal from how hard someone works to achieve it

November 23, 2017
Babies as young as 10 months can assess how much someone values a particular goal by observing how hard they are willing to work to achieve it, according to a new study from MIT and Harvard University.

Stress in pregnancy linked to changes in infant's nervous system, less smiling, less resilience

November 23, 2017
Maternal stress during the second trimester of pregnancy may influence the nervous system of the developing child, both before and after birth, and may have subtle effects on temperament, resulting in less smiling and engagement, ...

Domestic violence turns women off masculine men

November 23, 2017
Women who are afraid of violence within partnerships prefer more feminine men, according to new research carried out by scientists at the University of St Andrews.

Study finds infection and schizophrenia symptom link

November 22, 2017
If a mother's immune system is activated by infection during pregnancy, it could result in critical cognitive deficits linked to schizophrenia in her offspring, a University of Otago study has revealed.

Schizophrenia drug development may be 'de-risked' with new research tool

November 22, 2017
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) have identified biomarkers that can aid in the development of better treatments for schizophrenia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.